Rates of rectal cancer are increasing in the United States, reversing decades of decline in colorectal cancer according to recent reports. The shift is particularly pronounced among younger adults, with half of all colorectal cancer cases now diagnosed in individuals under the age of 65.
The trend, highlighted by reports from NBC News, the New York Times, and the Canadian Cancer Research Association (CCRAN), challenges conventional understanding of the disease, which historically affected primarily older populations. While overall colorectal cancer incidence has been decreasing due to improved screening and lifestyle factors, the rise in rectal cancer is prompting concern among medical professionals.
A comprehensive review published in the Journal of Gastrointestinal Cancer in October 2025, examined neoadjuvant treatment resistance in rectal cancer. The study, authored by Alexandru Micu and colleagues at the Fundeni Clinical Institute in Bucharest, Romania, underscores the complexities of treating locally advanced rectal cancer, which accounts for approximately one-third of all colorectal cancer diagnoses. The research focuses on overcoming challenges related to resistance to initial treatments, but does not directly address the rising incidence rates.
Colorectal cancer, encompassing cancers of the colon and rectum, develops from uncontrolled growth of cells in the large intestine. Symptoms can include blood in the stool, changes in bowel habits, unintentional weight loss, vomiting, and fatigue, according to information from Wikipedia. Risk factors include diet, obesity, smoking, lack of physical activity, and a history of inflammatory bowel disease.
The Canadian Cancer Research Association is currently urging Canadians to participate in colorectal cancer screening programs. This initiative comes as awareness of the disease grows, fueled in part by recent high-profile cases and a desire to improve early detection rates.
Research published in Annals of Oncology details efforts to predict the efficacy of neoadjuvant chemoradiotherapy (NACRT) in locally advanced rectal cancer (LARC) patients. NACRT is a standard treatment approach, followed by surgery and potential adjuvant therapy. The study aims to refine treatment strategies for LARC, but does not explain the increasing incidence of the disease.
